Low-Level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a New Regimen

REFERENCES

• Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126(12):929–938.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infec-tion. Ann Intern Med. 1997;126(12):946–954.
   PubMed Web of Science ®Google Scholar
• Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretro-viral therapy. J Infect Dis. 1998;177(1):40–47.
   PubMed Web of Science ®Google Scholar
• Thiébaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical pro-gression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). AIDS. 2000;14(8):971–978.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ, Reiss P Jr, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. JAMA. 2008;300(5):555–570.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Ado-lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed January 7, 2009.
   Google Scholar
• Gazzard BG, on behalf of the BHIVA Treatment Guide-lines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. Available at: http://www.bhiva.org/files/file1030835.pdf. Accessed January 7, 2009.
   Google Scholar
• Coakley EP, Doweiko JP, Bellosillo NA, D'Agata EM, Albrecht MA. HIV drug resistance profiles and clinical and virologic outcomes among HIV-infected subjects with stable detectable plasma viral loads<00 copies/mL for at least 12 months. Presented at: 9th Conference on Ret-roviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 556–T.
   Google Scholar
• Kantor R, Shafer R, Katzenstein D, Follansbee S, Fessel J. Evolution of reverse transcriptase and protease resis-tance mutations in HIV-1 infected patients on antiretroviral therapy. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 566–T.
   Google Scholar
• Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resis-tance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA. 2001 ;286(2):196–207.
   PubMed Web of Science ®Google Scholar
• Goetz MB, Moatamed F, Wrin T, Dawson K, Hellmann N. Long term durability of impaired HIV replication capacity (RC) in patients maintained on a stable treatment regi-men despite low-level virologic failure (VF). Presented at: 2nd International AIDS Society Conference on Patho-genesis and Treatment; July 13–17, 2003; Paris, France. Abstract 271.
   Google Scholar
• Tenorio AR, Smith KY, Kuritzkes DR, et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral sup-pression. J Acquir Immune Defic Syndr. 2003;34(5):491–496.
   PubMed Web of Science ®Google Scholar
• Morse C, Maldarelli F, Dewar R. Limited evolution of drug resistance in HIV-1 infected patients with persistent low-level viremia on a stable regimen for longer than 1 year. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, MA. Abstract 678.
   Google Scholar
• Sungkanuparph S, Groger R, Overton E, et al. Persistent low-level viraemia and virological failure in HIV-1 infected patients treated with highly active antiretroviral therapy. HIV Med. 2006;7:437–441.
   PubMed Web of Science ®Google Scholar
• Nasta P, Castelnuovo F, Paraninfo G. To maintain or to switch to HAART in heavily pre-treated patients with low-level viremia. Presented at: 12th Conference on Retrovi-ruses and Opportunistic Infections; February 22–25, 2005; Boston, MA. Abstract 605.
   Google Scholar
• Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18(7):981–989.
   PubMed Web of Science ®Google Scholar
• Karlsson AC, Younger S, Martin J, et al. Low-level antigenic exposure differentially affects T cell activation and HIV specific T cell response. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco, CA. Abstract 453.
   Google Scholar
• Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previ-ous suppression below the limits of quantification. AIDS. 2002 ;16(15):2035–2041.
   PubMed Web of Science ®Google Scholar
• Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16(14):1967–1969.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resis-tance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004:39(7):1030–1037.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Hittinger G, Delbeke E, Poggi C. Resistance selection with stable low levels of HIV-1 viremia. Presented at: XV International AIDS Conference; July 11–16, 2004; Bangkok, Thailand. Abstract WeOrB1293.
   Google Scholar
• Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sönnerborg A. Drug resistance at low viraemia in HIV-1 infected patients with antiretroviral combination therapy. AIDS. 2002;16(7):1039–1044.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis. 2004; 189(2):312–321.
   PubMed Web of Science ®Google Scholar
• Lo Re V III, Gasink L, Kostman JR, Leonard D, Gross R. Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs. 2004;18(8):436–442.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191 (3):348–357.
   PubMed Web of Science ®Google Scholar
• Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002;76(21)11104–11112.
   Web of Science ®Google Scholar
• Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:238–243.
   PubMed Web of Science ®Google Scholar
• Tirado G, Jove G, Kumar R, et al. Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations. Virology. 2004;324:577–586.
   PubMed Web of Science ®Google Scholar
• Tirado G, Jove G, Reyes E, et al. Differential evolution of cell-associated virus in blood and genital tract of HIV-infected families undergoing HAART. Virology. 2005;334:299–305.
   PubMed Web of Science ®Google Scholar
• Tirado G, Jove G, Yamamura Y. Vaginal HIV-1 shows distinct drug resistance mutation patterns compared to plasma HIV-1 and remain M-tropic despite advanced dis-ease. Antivir Ther. 2003;8:575. Abstract 68.
   Web of Science ®Google Scholar
• Günthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebro-spinal fluid after suppression of viremia for 2 years. J Infect Dis. 2001;183:1318–1327.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J Infect Dis. 1998;177(1): 235–238.
   PubMed Web of Science ®Google Scholar
• Mayer KH, Boswell S, Goldstein, etal. Persistence of human immunodeficiency virus in semen after adding indi-navir to combination antiretroviral therapy. Clin Infect Dis. 1999;28:1252–1259.
   PubMed Web of Science ®Google Scholar
• Liuzzi G, Chirianni A, Zaccarelli M, et al. Differences between semen and plasma of nucleoside reverse tran-scriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo. 2004;18:509–512.
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a viro-logically failing combination antiretroviral therapy regimen. AIDS. 2007;21:721–732.
   PubMed Web of Science ®Google Scholar
• Napravnik S, Edwards D, Stewart P, et al. HIV-drug resis-tance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr. 2005;40:34–40.
   PubMed Web of Science ®Google Scholar
• Karlsson AC, Hunt P, Sinclair E, et al. HIV specific immunity, T-cell activation and replicative capacity in antiretroviral treated adults experiencing intermittent versus persistent low-level viral replication. Antivir Ther. 2002;7:543.
   Web of Science ®Google Scholar
• Deeks, SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest. 2004;113(6): 808–810.
   Google Scholar
• PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected indi-viduals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51–62.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181(3):946–953.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201–207.
   PubMed Web of Science ®Google Scholar
• Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4:11.
   PubMedGoogle Scholar
• Hazenberg MD, Otto SA, van Benthem BHB, et al. Per-sistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–1888.
   PubMed Web of Science ®Google Scholar
• Ruane P, Gallant JE, Tennenberg A, Guzman SS. Safety and efficacy of darunavir in com low-dose ritonavir: 48-week results from the POWER studies. Presented at: Frontiers in Drug Development for Antiretroviral Therapies (HIV DART); December 10–14, 2006; Cancun, Mexico. Abstract 74.
   Google Scholar
• Miralles D, Hill A, Vangeneugden T, Lefebvre E. Durability of HIV RNA endpoints in treatment-experienced patients: analysis of POWER, RESIST and TORO trials. Presented at: 8th International Congress on Drug Therapy in HIV Infection; November 12–16, 2006; Glasgow, UK. Abstract P31.
   Google Scholar
• Lundgren JD, Babiker A, El-Sadr, etal, for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008:197:1145–1155.
   PubMed Web of Science ®Google Scholar
• Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS. 2004;18(18):2419–2423.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a ran-domized, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztein B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infec-tion. N Engl J Med. 2008;359:339–354.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441.
   PubMed Web of Science ®Google Scholar
• Johnson M, Campbell T, Clotet B. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 791.
   Google Scholar
• Haubrich R, Cahn P, Grinsztejn B. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 790.
   Google Scholar
• Zaccarelli M, Tozzi V, Forbici F, et al. Achieving undetect-able HIV viral load after genotypic resistance test dramati-cally decreases HIV progression and survival even in more advanced patients. Presented at: 5th European HIV Drug Resistance Workshop; March 28–30, 2007; Cascais, Portugal. Poster 93.
   Google Scholar
• Bracciale L, Colafigli M, Di Giambenedetto S, et al. Reaching undetectable HIV RNA levels is an independent predictor of AIDS-free survival in patients with 3-class resistant HIV-1. Presented at: 5th European HIV Drug Resistance Workshop; March 28–30, 2007; Cascais, Portugal. Poster 90.
   Google Scholar
• Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 2008 Jan 15;46(2):296–304.
   PubMed Web of Science ®Google Scholar
• Dane! C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a ran-domised trial. Lancet. 2006;367:1981–1989.
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–1178.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet. 2007;370:49–58.
   PubMed Web of Science ®Google Scholar
• Saag M, Lye P, Heera J, et al. A multicenter, randomised, double-blind, comparative trial of a novel CCR5 antago-nist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/Iamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: Week 48 results of the MERIT study. Presented at: 4th International AIDS Society (IAS) Conference; July 22–25, 2007; Sydney, Australia. Abstract WESS104.
   Google Scholar
• Alatrakchi N, Duvivier C, Costagliola D, et al. Persis-tent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS. 2005;19(1):25–33.
   PubMed Web of Science ®Google Scholar